AAV8-mediated <em>SIRT1</em> gene transfer to the liver prevents high carbohydrate diet-induced non-alcoholic fatty liver disease

dc.contributor.authorVilà Prats, Laia
dc.contributor.authorElias, Ivet
dc.contributor.authorRoca, Carles
dc.contributor.authorRibera Sánchez, Albert
dc.contributor.authorFerré Masferrer, Tura
dc.contributor.authorCasellas, Alba
dc.contributor.authorLage Rodrigues, Luis Ricardo
dc.contributor.authorFranckhauser, Sylvie
dc.contributor.authorBosch i Tubert, Fàtima
dc.date.accessioned2025-01-17T09:12:55Z
dc.date.available2025-01-17T09:12:55Z
dc.date.issued2014-10
dc.date.updated2025-01-17T09:12:55Z
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease worldwide, and evidence suggests that it promotes insulin resistance and type 2 diabetes. Caloric restriction (CR) is the only available strategy for NAFLD treatment. The protein deacetylase Sirtuin1 (SIRT1), which is activated by CR, increases catabolic metabolism and decreases lipogenesis and inflammation, both involved in the development of NAFLD. Here we show that adeno-associated viral vectors of serotype 8 (AAV8)-mediated liver-specific Sirt1 gene transfer prevents the development of NAFLD induced by a high carbohydrate (HC) diet. Long-term hepatic SIRT1 overexpression led to upregulation of key hepatic genes involved in β-oxidation, prevented HC diet-induced lipid accumulation and reduced liver inflammation. AAV8-Sirt1–treated mice showed improved insulin sensitivity, increased oxidative capacity in skeletal muscle and reduced white adipose tissue inflammation. Moreover, HC feeding induced leptin resistance, which was also attenuated in AAV8-Sirt1–treated mice. Therefore, AAV-mediated gene transfer to overexpress SIRT1 specifically in the liver may represent a new gene therapy strategy to counteract NAFLD and related diseases such as type 2 diabetes
dc.format.extent1 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec752462
dc.identifier.urihttps://hdl.handle.net/2445/217599
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/mtm.2014.39
dc.relation.ispartofMolecular Therapy. Methods & Clinical Development, 2014
dc.relation.urihttps://doi.org/10.1038/mtm.2014.39
dc.rightscc-by (c) Laia Vilà et al., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationDiabetis
dc.subject.classificationResistència a la insulina
dc.subject.classificationInsulina
dc.subject.otherDiabetes
dc.subject.otherInsulin resistance
dc.subject.otherInsulin
dc.titleAAV8-mediated <em>SIRT1</em> gene transfer to the liver prevents high carbohydrate diet-induced non-alcoholic fatty liver disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
872917.pdf
Mida:
1.48 MB
Format:
Adobe Portable Document Format